Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.56 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.53 |
| ▸ | TNKS | O95271 | 1/20 | 0.51 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 4/20 | 0.50 |
| ▸ | VNN1 | O95497 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.49 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.49 |
| ▸ | CCNC | P24863 | 2/20 | 0.46 |
| ▸ | CDK8 | P49336 | 2/20 | 0.46 |
| ▸ | WNT1 | P04628 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30159516 | 1.00 | MAOB (0.56) | MAOBMAOAACHEHCAR3TNKS | |
| SCHEMBL15332965 | 0.87 | MAOB (0.53) | MAOBMAOAACHETNKSTNKS2 | |
| SCHEMBL4410330 | 0.86 | MAOB (0.59) | MAOBMAOAACHEARVNN1 | |
| SCHEMBL29794165 | 0.86 | TNKS (0.52) | HCAR3TNKSTNKS2VNN1PTGER3 | |
| SCHEMBL1759304 | 0.86 | TNKS (0.52) | HCAR3TNKSTNKS2VNN1PTGER3 | |
| SCHEMBL27273152 | 0.85 | MAOB (0.58) | MAOBMAOAACHETNKSTNKS2 | |
| SCHEMBL30159522 | 0.85 | AR (0.66) | MAOBMAOAACHEARVNN1 | |
| SCHEMBL15875020 | 0.85 | AR (0.66) | MAOBMAOAACHEARVNN1 | |
| SCHEMBL23164615 | 0.84 | CREBBP (0.52) | ARNPC1ALDH1A1MAPTHPGD | |
| SCHEMBL30394909 | 0.84 | CREBBP (0.52) | ARNPC1ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| EP-4676929-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025262295-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667466-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| EP-4638447-A1 | IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS | Dark Blue Therapeutics Ltd (GB) | 2025-10-29 | — | — | EP | disclosed |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
| EP-4263546-B1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2025-07-02 | — | — | EP | disclosed |
| EP-4263547-B1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2025-07-02 | — | — | EP | disclosed |
| WO-2012149157-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC | 2012-05-03 | — | — | US | disclosed |
| WO-2012056372-A1 | N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012002527-A1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | あすか製薬株式会社 (JP) | 2012-01-05 | — | — | WO | disclosed |
| EP-2297163-A1 | PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS | Pfizer Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20110028390-A1 | Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110028390-A1 | Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110028390-A1 | Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| WO-2009144554-A1 | PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS | PFIZER, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009144554-A1 | PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS | PFIZER, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | MAOB 165/4885MAOA 182/4885ACHE 102/4885 |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, COASY | MAOB 930/4885MAOA 1174/4885ACHE 467/4885 |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | NEU1, NEU2, NEU4 | MAOB 343/4885MAOA 259/4885ACHE 141/4885 |
| US-20110028390-A1 | Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | MAOB 1784/4885MAOA 1807/4885ACHE 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.